Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program

Eribulin: A Novel Cytotoxic Chemotherapy Agent

(2012) Jessica N Preston et al.   ANNALS OF PHARMACOTHERAPY

Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin

(2012) Lot A. Devriese et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment

(2012) L. A. Devriese et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Antitumor Activity of Targeted and Cytotoxic Agents in Murine Subcutaneous Tumor Models Correlates with Clinical Response

(2012) H. Wong et al.   CLINICAL CANCER RESEARCH

Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole

(2012) L. A. Devriese et al.   INVESTIGATIONAL NEW DRUGS

Eribulin Mesylate

(2011) S. Jain et al.   CLINICAL CANCER RESEARCH

Eribulin mesylate in patients with refractory cancers: a Phase I study

(2011) Toru Mukohara et al.   INVESTIGATIONAL NEW DRUGS

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

(2011) Javier Cortes et al.   LANCET

Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes

(2011) Patrick Schöffski et al.   LANCET ONCOLOGY

Eribulin Induces Irreversible Mitotic Blockade: Implications of Cell-Based Pharmacodynamics forIn vivoEfficacy under Intermittent Dosing Conditions

(2010) Murray J. Towle et al.   CANCER RESEARCH

National Cancer Institute pediatric preclinical testing program: Model description for in vitro cytotoxicity testing

(2010) Min H. Kang et al.   PEDIATRIC BLOOD & CANCER

Interactions between the chemotherapeutic agent eribulin mesylate (E7389) and P-glycoprotein in CF-1 abcb1a-deficient mice and Caco-2 cells

(2010) Jan-Shiang Taur et al.   XENOBIOTICA

Eribulin Binds at Microtubule Ends to a Single Site on Tubulin To Suppress Dynamic Instability

(2009) Jennifer A. Smith et al.   BIOCHEMISTRY

A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

(2009) S. Goel et al.   CLINICAL CANCER RESEARCH

Phase I Study of Eribulin Mesylate Administered Once Every 21 Days in Patients with Advanced Solid Tumors

(2009) A. R. Tan et al.   CLINICAL CANCER RESEARCH

Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

(2009) Linda T. Vahdat et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II evaluation of intravenous vinorelbine (Navelbine) in recurrent or refractory pediatric malignancies: A Children's Oncology Group study

(2009) John F. Kuttesch et al.   PEDIATRIC BLOOD & CANCER

Clinical outcome in children with recurrent neuroblastoma treated with ABT-751 and effect of ABT-751 on proliferation of neuroblastoma cell lines and on tubulin polymerization in vitro

(2009) Holly J. Meany et al.   PEDIATRIC BLOOD & CANCER